EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse

Huan Xie, Ran Luo, Dongfeng Zeng

Archives of Medical Science · 21.08.2026

DOI: 10.5114/aoms/230992 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Archives of Medical Science, online erschienen am 21.08.2026. Verfasst von Huan Xie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Army Medical Center of PLA, Chongqing, China. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extramedullary disease (EMD) is an aggressive form of multiple myeloma (MM). The reported incidence ranges from 0.5% to 4.8% among patients with newly diagnosed MM

Autor:innen und Institutionen

  • Department of Hematology, Army Medical Center of PLA, Chongqing, China.

Zitieren

APA

Xie, H., Luo, R., & Zeng, D. (2026). Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse. Archives of Medical Science. https://doi.org/10.5114/aoms/230992

Vancouver

Xie H, Luo R, Zeng D. Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse. Archives of Medical Science. 2026. doi:10.5114/aoms/230992

BibTeX
@article{Xie2026,
  author = {Xie, Huan and Luo, Ran and Zeng, Dongfeng},
  title = {Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse},
  journal = {Archives of Medical Science},
  year = {2026},
  doi = {10.5114/aoms/230992}
}
Kostenlos starten →